Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

References

• Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015;14(9):603–622. eng. doi:10.1038/nrd4596.
   PubMed Web of Science ®Google Scholar
• Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15(8):471–485. eng. doi:10.1038/nri3865.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–414. eng. doi:10.1038/nri3845.
   PubMed Web of Science ®Google Scholar
• Barchet W, Wimmenauer V, Schlee M, Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol. 2008;20(4):389–395. eng. doi:10.1016/j.coi.2008.07.007.
   PubMed Web of Science ®Google Scholar
• Kobold S, Wiedemann G, Rothenfußer S, Endres S. Modes of action of TLR7 agonists in cancer therapy. Immunotherapy. 2014;6(10):1085–1095. eng. doi:10.2217/imt.14.75.
   PubMed Web of Science ®Google Scholar
• Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest. 2012;122(2):575–585. eng. doi:10.1172/JCI61034.
   PubMed Web of Science ®Google Scholar
• Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 2013;73(15):4629–4640. eng. doi:10.1158/0008-5472.CAN-12-3058.
   PubMed Web of Science ®Google Scholar
• Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity. 2010;33(6):955–966. eng. doi:10.1016/j.immuni.2010.11.020.
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. 2017;31(10):2278. eng. doi:10.1038/leu.2017.218.
   PubMed Web of Science ®Google Scholar
• Doorduijn EM, Sluijter M, Salvatori DC, Silvestri S, Maas S, Arens R, Ossendorp F, van der Burg SH, van Hall T. CD4+ T cell and NK cell interplay key to regression of MHC class ilow tumors upon TLR7/8 agonist therapy. Cancer Immunol Res. 2017;5(8):642–653. eng. doi:10.1158/2326-6066.CIR-16-0334.
   PubMed Web of Science ®Google Scholar
• Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP. TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res. 2008;28(4):253–263. eng. doi:10.1089/jir.2007.0097.
   PubMed Web of Science ®Google Scholar
• Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, Borden EC. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res. 1993;53(21):5176–5180. eng.
   PubMed Web of Science ®Google Scholar
• Holldack J. Toll-like receptors as therapeutic targets for cancer. Drug Discov Today. 2014;19(4):379–382. eng. doi:10.1016/j.drudis.2013.08.020.
   PubMed Web of Science ®Google Scholar
• Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–733. eng. doi:10.1016/j.jaad.2003.11.066.
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, et al. Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Cancer Immunol Immunother. 2010;59(12):1877–1884. eng. doi:10.1007/s00262-010-0914-1.
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Cooley S, DeFor T, Weisdorf DJ, Panoskaltsis-Mortari A, Chen W, Blazar BR, Miller JS. Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. Am J Hematol. 2012;87(10):953–956. eng. doi:10.1002/ajh.23280.
   PubMed Web of Science ®Google Scholar
• Christian LM, Porter K, Karlsson E, Schultz-Cherry S. Proinflammatory cytokine responses correspond with subjective side effects after influenza virus vaccination. Vaccine. 2015;33(29):3360–3366. eng. doi:10.1016/j.vaccine.2015.05.008.
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005;174(3):1259–1268. eng.
   PubMed Web of Science ®Google Scholar
• Hamm S, Rath S, Michel S, Baumgartner R. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol. 2009;6(4):257–265. eng. doi:10.3109/15476910903286733.
   PubMed Web of Science ®Google Scholar
• Wiedemann GM, Jacobi SJ, Chaloupka M, Krächan A, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S, et al. A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice. Oncoimmunology. 2016;5(7):e1189051. eng. doi:10.1080/2162402X.2016.1189051.
   PubMed Web of Science ®Google Scholar
• Yin P, Liu X, Mansfield AS, Harrington SM, Li Y, Yan Y, Dong H. CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. Oncotarget. 2016;7(43):70223–70231. eng. doi:10.18632/oncotarget.11833.
   PubMedGoogle Scholar
• Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 2011;71(15):5123–5133. eng. doi:10.1158/0008-5472.CAN-10-3903.
   PubMed Web of Science ®Google Scholar
• Koga-Yamakawa E, Murata M, Dovedi SJ, Wilkinson RW, Ota Y, Umehara H, Sugaru E, Hirose Y, Harada H, Jewsbury PJ, et al. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Cancer Immunol Immunother. 2015;64(10):1229–1239. eng. doi:10.1007/s00262-015-1730-4.
   PubMed Web of Science ®Google Scholar
• Tsitoura D, Ambery C, Price M, Powley W, Garthside S, Biggadike K, Quint D. Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015;98(4):369–380. eng. doi:10.1002/cpt.157.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301–1309. eng. doi:10.1038/nm.3708.
   PubMed Web of Science ®Google Scholar
• Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, et al. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med. 2017;9(407). eng. doi:10.1126/scitranslmed.aal4712.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413(6857):732–738. eng. doi:10.1038/35099560.
   PubMed Web of Science ®Google Scholar
• Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood. 2006;108(10):3253–3261. eng. doi:10.1182/blood-2006-06-027599.
   PubMed Web of Science ®Google Scholar
• Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918–1921. eng. doi:10.1126/science.8009221.
   PubMed Web of Science ®Google Scholar
• Wexler H. Accurate identification of xperimental pulmonary metastases. J Natl Cancer Inst. 1966;36(4):641–645. eng. doi:10.1093/jnci/36.4.641.
   PubMedGoogle Scholar
• Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O, Sahin U. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010;70(22):9031–9040. eng. doi:10.1158/0008-5472.CAN-10-0699.
   PubMed Web of Science ®Google Scholar